SIGNIFOR LAR POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 60MG [SIN15170P]
Active ingredients: PASIREOTIDE PAMOATE 82.26 MG EQV PASIREOTIDE
Last updated on 9 October 2026
Product Info
SIGNIFOR LAR POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION 60MG
[SIN15170P]
Product information
Active Ingredient and Strength | PASIREOTIDE PAMOATE 82.26 MG EQV PASIREOTIDE - 60 MG |
Dosage Form | INJECTION, POWDER, FOR SUSPENSION |
Manufacturer and Country | RECORDATI AG RARE DISEASES BRANCH (MANUFACTURE OF BULK POWDER) - SWITZERLAND |
Registration Number | SIN15170P |
Licence Holder | PHARM-D SINGAPORE PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | H01CB05 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
INDICATIONS
Signifor LAR is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
Dosing
DOSAGE REGIMEN AND ADMINISTRATION
Dosage regimen
General target population
The recommended initial dose of Signifor LAR is 40 mg administered by deep intramuscular injection every 4 weeks (q28d).
The dose may be increased to a maximum of 60 mg for patients whose GH and/or IGF-1 levels are not fully controlled after 3 months of treatment with Signifor LAR at 40 mg.
Management of suspected adverse reactions or over response to treatment (IGF-1 < lower limit of normal) may require dose reduction of Signifor LAR. The dose may be decreased, either temporarily or permanently, by 20 mg decrements.
Missed dose
If a dose of Signifor LAR is missed, the injection should be administered as soon as possible and the next injection should be planned 4 weeks thereafter to resume normal schedule every 4 weeks.
Special populations
Renal impairment
No dose adjustment is required in patients with impaired renal function (see section CLINICAL PHARMACOLOGY – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Hepatic impairment
Dose adjustment is not required in patients with mildly impaired hepatic function (Child-Pugh A). For patients with moderately impaired hepatic function (Child-Pugh B) the recommended initial dose is 20 mg every 4 weeks and the maximum recommended dose is 40 mg every 4 weeks (see section CLINICAL PHARMACOLOGY – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Signifor LAR should not be used in patients with severe hepatic impairment (Child-Pugh C) (see section CONTRAINDICATIONS).
Pediatric patients
Signifor LAR is not recommended for use in pediatric patients with acromegaly as there are no clinical data available in patients under 18 years of age.
Geriatric patients (65 years of age or older)
There are limited data on the use of Signifor LAR in patients older than 65 years but there is no evidence suggesting that a dose adjustment is required in elderly patients (see section CLINICAL PHARMACOLOGY – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Method of administration
Signifor LAR should only be administered by deep intramuscular injection by a trained health care professional. Signifor LAR suspension must only be prepared immediately before administration. The site of repeat intramuscular injections should be alternated between the left and right gluteal muscle (see section INSTRUCTIONS FOR USE AND HANDLING – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Contraindications
CONTRAINDICATIONS
Severe hepatic impairment (Child-Pugh C).